Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22146TDB-ST

Select Item

Placenta Growth Factor Pipeline Drugs Market Report Overview

The Placenta Growth Factor pipeline drugs market research report outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.

Placenta Growth Factor Pipeline Drugs Market by Key Therapy Areas

The key therapy areas in the Placenta Growth Factor pipeline drugs market are ophthalmology, metabolic disorders, and oncology.

Placenta Growth Factor Pipeline Drugs Market, by Therapy Areas

Placenta Growth Factor Pipeline Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanism of Actions in the Placenta Growth Factor Pipeline Drugs Market

The key mechanism of action in the Placenta Growth Factor pipeline drugs market is Placenta Growth Factor Inhibitor.

Key Routes of Administration in the Placenta Growth Factor Pipeline Drugs Market

The key routes of administration in the Placenta Growth Factor pipeline drugs market are intravitreal, intravenous, parenteral, subconjunctival, intraocular, and ophthalmic.

Placenta Growth Factor Pipeline Drugs Market, by Routes of Administration

Placenta Growth Factor Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Placenta Growth Factor Pipeline Drugs Market

The key molecule types in the Placenta Growth Factor pipeline drugs market are fusion protein, monoclonal antibody, and gene therapy.

Placenta Growth Factor Pipeline Drugs Market, by Molecule Types

Placenta Growth Factor Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Placenta Growth Factor Pipeline Drugs Market

The key companies in the Placenta Growth Factor pipeline drugs market are Luye Pharma Group Ltd, Alteogen Inc, Alvotech SA, Amgen Inc, Celltrion Inc, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Cinnagen Co, Formycon AG, GlycoNex Inc, and Hexal AG.

Placenta Growth Factor Pipeline Drugs Market, by Companies

Placenta Growth Factor Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

Placenta Growth Factor Pipeline Drugs Market Report Overview

Key Therapy Areas Ophthalmology, Metabolic Disorders, and Oncology
Key Mechanism of Actions Placenta Growth Factor Inhibitor
Key Routes of Administration Intravitreal, Intravenous, Parenteral, Subconjunctival, Intraocular, and Ophthalmic
Key Molecule Types Fusion Protein, Monoclonal Antibody, and Gene Therapy
Key Companies Luye Pharma Group Ltd, Alteogen Inc, Alvotech SA, Amgen Inc, Celltrion Inc, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Cinnagen Co, Formycon AG, GlycoNex Inc, and Hexal AG

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).
  • Reviews of Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects.
  • Assessment of Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summarization of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.

  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).

  • Identify the use of drugs for target identification and drug repurposing.

  • Identify potential new clients or partners in the target demographic.

  • Develop strategic initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.

  • Devise corrective measures for pipeline projects by understanding the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Alteogen Inc
Alvotech SA
Amgen Inc
Celltrion Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cinnagen Co
Formycon AG
GlycoNex Inc
Hexal AG
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Johnson & Johnson
Kidswell Bio Corp
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Neuracle Genetics Inc
Ocular Therapeutix Inc
Oncosimis Biotech Pvt Ltd
Oxurion NV
Panolos Bioscience
PharmAbcine Inc
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Rophibio Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd
Shilpa Medicare Ltd
Synermore Biologics Co Ltd
Zeen Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Companies Involved in Therapeutics Development

Alteogen Inc

Alvotech SA

Amgen Inc

Celltrion Inc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Cinnagen Co

Formycon AG

GlycoNex Inc

Hexal AG

Huons Global Co Ltd

i2 Pharmaceuticals Inc

Johnson & Johnson

Kidswell Bio Corp

Luye Pharma Group Ltd

Mabwell Shanghai Bioscience Co Ltd

Neuracle Genetics Inc

Ocular Therapeutix Inc

Oncosimis Biotech Pvt Ltd

Oxurion NV

Panolos Bioscience

PharmAbcine Inc

Prestige BioPharma Ltd

Regeneron Pharmaceuticals Inc

Rophibio Inc

Sam Chun Dang Pharm Co Ltd

Samsung Bioepis Co Ltd

Shilpa Medicare Ltd

Synermore Biologics Co Ltd

Zeen Biotechnology Co Ltd

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Drug Profiles

aflibercept – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

aflibercept SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

conbercept – Drug Profile

Product Description

Mechanism Of Action

History of Events

KH-906 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NG-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PB-101 – Drug Profile

Product Description

Mechanism Of Action

SL-186 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SL-188 – Drug Profile

Product Description

Mechanism Of Action

History of Events

THR-317 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-aflibercept – Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-aflibercept biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Product Development Milestones

Featured News & Press Releases

Jul 14, 2022: New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer

Jul 07, 2022: Alvotech initiates patient study for AVT06, a proposed biosimilar for Eylea

Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review

Apr 25, 2022: Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept

Feb 22, 2022: Bayer Gets Eylea Biosame approval in Japan as it braces for biosimilar debuts

Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting

Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies

Aug 25, 2021: Regeneron’s aflibercept meets primary goal in Phase II wet AMD trial

Jul 27, 2021: Humana Sues Regeneron Over Price Of Eylea Macular Degeneration Drug

May 04, 2021: Sandoz to study biosimilar aflibercept in Phase III AMD trial

Apr 12, 2021: Oncurious reports encouraging data from phase 1 dose escalation study of TB-403 in paediatric subjects with relapsed or refractory medulloblastoma presented at the American Association for Cancer Research 2021 Annual Meeting

Apr 09, 2021: Kanghong Pharmaceutical stops clinical study of ocular drug Conbercept

Apr 09, 2021: ONCURIOUS presenting clinical and preclinical data at upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting

Mar 31, 2021: Regeneron’s Eylea lowers vision-threatening events in diabetes trial

Mar 28, 2021: Kanghong pharmaceutical: khb-1802 clinical trial suspended in France

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more